Skip to main content

Anti-Tumor Necrosis Factor (TNF) Utilization Among Pregnant Women

    Basic Details
    Date Posted
    Status
    Complete
    Medical Product
    adalimumab
    certolizumab
    etanercept
    golimumab
    infliximab
    tumor necrosis factor (TNF) alpha inhibitor
    Description

    This report contains estimates of use of five tumor necrosis factor (TNF)-alpha inhibitors, etanercept, adalimumab, infliximab, certolizumab, and golimumab, that occurred during a pregnancy resulting in a liveborn delivery, or within 90 days prior to the estimated start of pregnancy. The query was run against the Sentinel Distributed Database (SDD) for the time period of January 1, 2004 to September 30, 2015. This request was distributed to 16 Data Partners on June 27, 2017.

    Additional Details
    FDA Center
    CDER
    Time Period
    January 1, 2004 - September 30, 2015
    Analysis Type
    Descriptive
    Population / Cohort
    Females 15 to 54 years of age
    Data Sources
    Sentinel Distributed Database (SDD)